NASDAQ:ASLN - ASLAN PHARMACEU/ADR Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.19 -0.01 (-0.31 %)
(As of 02/15/2019 04:00 PM ET)
Previous Close$3.19
Today's Range$3.14 - $3.25
52-Week Range$2.51 - $10.44
Volume13,729 shs
Average Volume29,425 shs
Market Capitalization$102.16 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in developing therapeutics for global markets. It targets diseases that are highly prevalent in Asia, and orphan indications in the United States and Europe. The company's product pipeline includes Varlitinib, a reversible small molecule pan-human epidermal growth factor receptor inhibitor that is being studied in global pivotal trials (TreeTopp) for biliary tract cancer, and conducting Phase 2/3 clinical trials for gastric cancer, as well as testing in a single-arm pivotal clinical trial in biliary tract cancer in China. It has exclusive global rights to develop, manufacture, and commercialize varlitnib for all human and animal therapeutic, diagnostic, and prophylactic uses. It is also developing ASLAN003, an orally active potent inhibitor of human dihydroorotate dehydrogenase that is in Phase 2 clinical trails to treat acute myeloid leukemia; and ASLAN004, an interleukin 4/interleukin 13 receptor antibody for the treatment of severe atopic dermatitis and asthma. The company has partnerships with Array BioPharma, Bristol-Myers Squibb, Almirall, and CSL. ASLAN Pharmaceuticals Limited was founded in 2010 and is headquartered in Singapore.

Receive ASLN News and Ratings via Email

Sign-up to receive the latest news and ratings for ASLN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ASLN
CUSIPN/A
Phone65-6222-4235

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees47
Market Cap$102.16 million
OptionableNot Optionable

ASLAN PHARMACEU/ADR (NASDAQ:ASLN) Frequently Asked Questions

What is ASLAN PHARMACEU/ADR's stock symbol?

ASLAN PHARMACEU/ADR trades on the NASDAQ under the ticker symbol "ASLN."

What price target have analysts set for ASLN?

4 analysts have issued 12-month price targets for ASLAN PHARMACEU/ADR's shares. Their forecasts range from $7.00 to $16.00. On average, they expect ASLAN PHARMACEU/ADR's share price to reach $10.50 in the next twelve months. This suggests a possible upside of 229.2% from the stock's current price. View Analyst Price Targets for ASLAN PHARMACEU/ADR.

What is the consensus analysts' recommendation for ASLAN PHARMACEU/ADR?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ASLAN PHARMACEU/ADR in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ASLAN PHARMACEU/ADR.

What are Wall Street analysts saying about ASLAN PHARMACEU/ADR stock?

Here are some recent quotes from research analysts about ASLAN PHARMACEU/ADR stock:
  • 1. HC Wainwright analysts commented, "We note that approved irreversible pan-HER inhibitors have not shown meaningful clinical efficacy in TNBC. These newly published preclinical data have demonstrated that varlitinib is able to inhibit migration, invasion and mammosphere formation in TNBC cells, and therefore, has the potential to deliver clinically meaningful efficacy. Reversible inhibitors could also have a better safety profile than irreversible drugs. We believe ASLAN could seek a partner for further development of varlitinib in TNBC. In the wake of this update, we reiterate our Buy rating and $8.50 price target. Varlitinib showed positive efficacy in first-line BTC. Last week, ASLAN Pharmaceuticals reported positive preliminary data from the ongoing Phase 1b/2 trial of varlitinib + gemcitabine and cisplatin (gem/cis) in first-line biliary tract cancer (BTC)." (1/24/2019)
  • 2. According to Zacks Investment Research, "ASLAN Pharmaceuticals Limited operates as a clinical-stage biotechnology company. It develops drugs, medicines and novel therapeutics for the treatment of patients with oncology, respiratory and inflammatory diseases. The company's product portfolio includes Varlitinib, ASLAN004, ASLAN002 and ASLAN003 both are in clinical stage. ASLAN Pharmaceuticals Limited is based in Singapore. " (1/16/2019)

Has ASLAN PHARMACEU/ADR been receiving favorable news coverage?

News coverage about ASLN stock has trended somewhat negative recently, according to InfoTrie Sentiment. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ASLAN PHARMACEU/ADR earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days.

Who are some of ASLAN PHARMACEU/ADR's key competitors?

Who are ASLAN PHARMACEU/ADR's key executives?

ASLAN PHARMACEU/ADR's management team includes the folowing people:
  • Dr. Carl Alan Jason Morton Firth, Chairman & CEO (Age 46)
  • Mr. Kiran Asarpota, VP of Fin. (Age 40)
  • Dr. Mark McHale, Chief Operating Officer (Age 54)
  • Charlie Hsu, Investor Relations Director
  • Mr. Ben Goodger, Gen. Counsel (Age 56)

When did ASLAN PHARMACEU/ADR IPO?

(ASLN) raised $60 million in an IPO on Friday, May 4th 2018. The company issued 7,500,000 shares at $8.05 per share. Leerink Partners and Piper Jaffray served as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers.

Who are ASLAN PHARMACEU/ADR's major shareholders?

ASLAN PHARMACEU/ADR's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Hsbc Holdings PLC (1.68%), FNY Investment Advisers LLC (0.08%) and Millennium Management LLC (0.06%).

Which institutional investors are selling ASLAN PHARMACEU/ADR stock?

ASLN stock was sold by a variety of institutional investors in the last quarter, including Hsbc Holdings PLC and Millennium Management LLC.

Which institutional investors are buying ASLAN PHARMACEU/ADR stock?

ASLN stock was acquired by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC.

How do I buy shares of ASLAN PHARMACEU/ADR?

Shares of ASLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ASLAN PHARMACEU/ADR's stock price today?

One share of ASLN stock can currently be purchased for approximately $3.19.

How big of a company is ASLAN PHARMACEU/ADR?

ASLAN PHARMACEU/ADR has a market capitalization of $102.16 million. ASLAN PHARMACEU/ADR employs 47 workers across the globe.

What is ASLAN PHARMACEU/ADR's official website?

The official website for ASLAN PHARMACEU/ADR is http://www.aslanpharma.com.

How can I contact ASLAN PHARMACEU/ADR?

ASLAN PHARMACEU/ADR's mailing address is 83 CLEMENCEAU AVENUE 12-03 UE SQUARE, SINGAPORE U0, 239920. The company can be reached via phone at 65-6222-4235 or via email at [email protected]


MarketBeat Community Rating for ASLAN PHARMACEU/ADR (NASDAQ ASLN)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  66 (Vote Outperform)
Underperform Votes:  86 (Vote Underperform)
Total Votes:  152
MarketBeat's community ratings are surveys of what our community members think about ASLAN PHARMACEU/ADR and other stocks. Vote "Outperform" if you believe ASLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel